In contrast, AM8096 responded poorly to quizartinib (Supplement Fig. S6), suggesting that wild type FLT3 is not a leukemogenic driver in this model and narazaciclib might provide advantageous anti-AML effects over quizartinib for patients with wild type FLT3. The gene discussed is FLT3; the disease is acute myeloid leukemia.